Company Profile of Bormioli Pharma

Bormioli Pharma: a quality, data-based partner for the pharma industry, enabling sustainability and mobilizing innovation

Bormioli Pharma is an international leader in the production of pharmaceutical packaging and medical devices, with a global presence in over 100 countries, the company counts more than 1,400 employees and 9 plants in Europe, specialized in the manufacturing of primary packaging and accessories for pharmaceutical, generics and biotech companies and CMOs.

It is fully owned by the investment firm Triton, a pan-European investment fund, which invests in medium-sized companies all over Europe.

Since the company has been acquired by Triton, in 2017, Bormioli Pharma has continued to grow and expand, pursuing its mission: making health a positive practice, accessible to everyone, kind to the planet.

Even more robust, reliable and global.

In the last three years, Bormioli Pharma has undertaken a consolidation process, through both investments in the existing plants and M&As in Continental Europe.

As a result of this process, the company enhanced its production platform both for molded and tubing glass, also producing in-house accessories such as closures, rubber stoppers and dropper pipettes, becoming the one-stop solution for the pharmaceutical industry.

Moreover, the company has become a truly global one, thanks to the opening of commercial offices overseas in USA and in China, where Bormioli Pharma is present with a sales branch in Shanghai.

A comprehensive product offering, addressing every pharma need.

The company's product offerings encompass tubing and moulded glass containers, plastic packaging - including environmentally responsible options made from bio-based or recycled materials - closures, rubber stoppers, aluminium seals, and packaging accessories like measuring cups and spoons.

With more than 680 products, Bormioli Pharma’s products and packaging offering are segmented into three Portfolios, addressing different market destinations and needs of the pharmaceutical industry, health professionals, and patients:

• forTherapy: packaging systems for high-value, prescription drugs
• forHealth: packaging solutions for daily medications and OTCs
• forLife: packaging kits for nutraceuticals and food supplements

Such organization allows customers to configure their complete packaging leveraging on a single supplier, confirming Bormioli Pharma’s key role as a fundamental and effective partner since the first phases of clinical trials. 

Innovating to make the difference.

Bormioli Pharma counts on Invents, an innovation platform, aimed at turning emerging healthcare trends and needs into industrial solutions.

The platform benefits from a robust ecosystem of partners, including partnerships with Innovation Hubs and accelerators, allowing the Group to stay on the edge of innovation, using a crowdsourcing approach to multiply and accelerate its development efforts.

With this new platform, Bormioli Pharma confirms its role as a forerunner in innovation in the pharmaceutical packaging world, making drug administration simpler, easier, and more accessible for everyone, including the elderly and people with disabilities.

Sustainability as a deep commitment towards industry, people and planet.

Bormioli Pharma has pledged to sustainability over 15 years ago, putting a huge focus on sustainable packaging products research.

The most evident outcome of this research is the fact that nowadays the 50% of the company’s catalogue is EcoPositive, which consists of a range of environmentally responsible, market-ready solutions ensuring reduced environmental impact and positioning Bormioli Pharma among those companies with the widest sustainable offering on the market.

Besides continuous R&D efforts on new, sustainable materials, Bormioli Pharma pursues a wider Environment, Social and Governance (ESG) strategy, leading to the annual publication of the Company’s ESG Report.